Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia
Authors:
- Michele PohlenMPMichele Pohlen
- Bülent SarginBSBülent Sargin
- Carsten Müller‐TidowCMCarsten Müller‐Tidow
- Steffen KoschmiederSKSteffen Koschmieder
- 11 March 2010
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 84 (4) , 362-364
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITPBlood, 2009
- Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialThe Lancet, 2008
- Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)Blood, 2007
- AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITPNew England Journal of Medicine, 2006
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.Journal of Clinical Investigation, 1987